Thr119 and Ser93 phosphorylation of BECN1 may be used as a predictive marker for poor prognosis in ovarian cancer, as well as a marker for the potential benefit of ovarian cancer drug therapy and early identification of drug resistance. This evidence concerns the gene BECN1 and ovarian carcinoma.